

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a)  
of the Securities Exchange Act of 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the SEC Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to 14a-12

**VISTAGEN THERAPEUTICS, INC.**  
(Name of Registrant as Specified in its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- No fee required
- Fee paid previously with preliminary materials
- Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



**Online**

Go to [www.envisionreports.com/VTGN](http://www.envisionreports.com/VTGN) or scan the QR code – login details are located in the shaded bar below.

**Notice of the Vistagen Therapeutics, Inc. 2025 Annual Meeting of Stockholders**

**Important Notice Regarding the Availability of Proxy Materials for the Vistagen Therapeutics, Inc. 2025 Annual Meeting of Stockholders to be Held on September 9, 2025**

Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the Vistagen Therapeutics, Inc. (the *Company*) 2025 Annual Meeting of Stockholders (the *Annual Meeting*) are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and instructions for virtually attending the Annual Meeting are on the reverse side. Your vote is important!

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Notice, Proxy Statement and Annual Report on Form 10-K for the year ended March 31, 2025 are available at:

[www.envisionreports.com/VTGN](http://www.envisionreports.com/VTGN)



**Easy Online Access – View your proxy materials and vote.**

- Step 1: Go to [www.envisionreports.com/VTGN](http://www.envisionreports.com/VTGN).
- Step 2: Click on **Cast Your Vote** or **Request Materials**.
- Step 3: Follow the instructions on the screen to log in.
- Step 4: Make your selections as instructed on each screen for your delivery preferences.
- Step 5: Vote your shares.

When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.



**Obtaining a Copy of the Proxy Materials** – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before August 29, 2025 to facilitate timely delivery.



2 N O T



046AWD

## Notice of the Vistagen Therapeutics, Inc. 2025 Annual Meeting of Stockholders

Vistagen Therapeutics, Inc.'s (the *Company*) 2025 Annual Meeting of Stockholders (the *Annual Meeting*) will be held on Tuesday, September 9, 2025, at 9:00 am PDT, virtually via the Internet at [www.meetnow.global/MMRS64D](http://www.meetnow.global/MMRS64D). To access the virtual Annual Meeting, you must have the information that is printed in the shaded bar located on the reverse side of this form.

Proposals to be voted on at the Annual Meeting are listed below, along with the Board of Directors' recommendations.

The Board of Directors recommends a vote FOR each Director nominee identified under Proposal No. 1 below and FOR Proposals No. 2 and No. 3:

1. Nominees: Margaret M. FitzPatrick, M.A., Ann M. Cunningham, MBA, Joanne Curley, Ph.D., Mary L. Rotunno, J.D., Jon S. Saxe, J.D., LL.M., and Shawn K. Singh, J.D.
2. To approve, on a non-binding advisory basis, the compensation paid to the Company's named executive officers (*NEOs*);
3. To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for our fiscal year ending March 31, 2026; and
4. To vote upon such other matters, if any, as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting.

**PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE.** To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card.



### Here's how to order a copy of the proxy materials and select delivery preferences:

Current and future delivery requests can be submitted using the options below.

If you request an email copy, you will receive an email with a link to the current Annual Meeting materials.

**PLEASE NOTE:** You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials.

- **Internet** – Go to [www.envisionreports.com/VTGN](http://www.envisionreports.com/VTGN). Click Cast Your Vote or Request Materials.
- **Phone** – Call us free of charge at 1-866-641-4276.
- **Email** – Send an email to [investorvote@computershare.com](mailto:investorvote@computershare.com) with "Proxy Materials Vistagen Therapeutics, Inc." in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials.

To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by August 29, 2025.